Dupilumab-Associated Sezary Syndrome

Dupilumab-Associated Sezary Syndrome

Dupilumab is a monoclonal antibody that inhibits interleukin-4 (IL-4) and interleukin-13 (IL-13), approved for the treatment of adults with moderate-to-severe atopic dermatitis (AD). While recent reports have described cases of new-onset mycosis fungoides (MF) following treatment with dupilumab for...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Indian journal of dermatology 2023, Vol.68 (4), p.459-462
Hauptverfasser: Hamp, Austin, Hanson, Jamie, Alhatem, Albert, Schwartz, Robert A
Format: Report
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 462
container_issue 4
container_start_page 459
container_title Indian journal of dermatology
container_volume 68
creator Hamp, Austin
Hanson, Jamie
Alhatem, Albert
Schwartz, Robert A
description Dupilumab is a monoclonal antibody that inhibits interleukin-4 (IL-4) and interleukin-13 (IL-13), approved for the treatment of adults with moderate-to-severe atopic dermatitis (AD). While recent reports have described cases of new-onset mycosis fungoides (MF) following treatment with dupilumab for AD, to our knowledge only one patient has been delineated with the progression to SS. We present an additional case of a patient who was diagnosed with SS following treatment with dupilumab for adult-onset AD and asthma. We examine SS as a possible side effect of dupilumab while also discussing management and theories to explain this phenomenon.
doi_str_mv 10.4103/ijd.ijd_580_22
format Report
fullrecord <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_miscellaneous_2876637377</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2876637377</sourcerecordid><originalsourceid>FETCH-proquest_miscellaneous_28766373773</originalsourceid><addsrcrecordid>eNpjYBAzNNAzMTQw1s_MStED4nhTC4N4IyMmBk5DS0sLXWMzQ0MOBq7i4iwDAxNjQwtDTgYVl9KCzJzS3MQkXcfi4vzkzMSS1BSF4NSqxKJKheDKvJSi_NxUHgbWtMSc4lReKM3NoOHmGuLsoVtQlF9YmlpcEp-bWZycmpOTmJeaX1ocb2RhbmZmbG5sbm5MglIAwGI4cg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>report</recordtype><pqid>2876637377</pqid></control><display><type>report</type><title>Dupilumab-Associated Sezary Syndrome</title><source>PubMed Central Free</source><source>DOAJ Directory of Open Access Journals</source><source>PubMed Central Open Access</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Hamp, Austin ; Hanson, Jamie ; Alhatem, Albert ; Schwartz, Robert A</creator><creatorcontrib>Hamp, Austin ; Hanson, Jamie ; Alhatem, Albert ; Schwartz, Robert A</creatorcontrib><description>Dupilumab is a monoclonal antibody that inhibits interleukin-4 (IL-4) and interleukin-13 (IL-13), approved for the treatment of adults with moderate-to-severe atopic dermatitis (AD). While recent reports have described cases of new-onset mycosis fungoides (MF) following treatment with dupilumab for AD, to our knowledge only one patient has been delineated with the progression to SS. We present an additional case of a patient who was diagnosed with SS following treatment with dupilumab for adult-onset AD and asthma. We examine SS as a possible side effect of dupilumab while also discussing management and theories to explain this phenomenon.</description><identifier>EISSN: 1998-3611</identifier><identifier>DOI: 10.4103/ijd.ijd_580_22</identifier><language>eng</language><ispartof>Indian journal of dermatology, 2023, Vol.68 (4), p.459-462</ispartof><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>780,784,864,4490,27925</link.rule.ids></links><search><creatorcontrib>Hamp, Austin</creatorcontrib><creatorcontrib>Hanson, Jamie</creatorcontrib><creatorcontrib>Alhatem, Albert</creatorcontrib><creatorcontrib>Schwartz, Robert A</creatorcontrib><title>Dupilumab-Associated Sezary Syndrome</title><title>Indian journal of dermatology</title><description>Dupilumab is a monoclonal antibody that inhibits interleukin-4 (IL-4) and interleukin-13 (IL-13), approved for the treatment of adults with moderate-to-severe atopic dermatitis (AD). While recent reports have described cases of new-onset mycosis fungoides (MF) following treatment with dupilumab for AD, to our knowledge only one patient has been delineated with the progression to SS. We present an additional case of a patient who was diagnosed with SS following treatment with dupilumab for adult-onset AD and asthma. We examine SS as a possible side effect of dupilumab while also discussing management and theories to explain this phenomenon.</description><issn>1998-3611</issn><fulltext>true</fulltext><rsrctype>report</rsrctype><creationdate>2023</creationdate><recordtype>report</recordtype><recordid>eNpjYBAzNNAzMTQw1s_MStED4nhTC4N4IyMmBk5DS0sLXWMzQ0MOBq7i4iwDAxNjQwtDTgYVl9KCzJzS3MQkXcfi4vzkzMSS1BSF4NSqxKJKheDKvJSi_NxUHgbWtMSc4lReKM3NoOHmGuLsoVtQlF9YmlpcEp-bWZycmpOTmJeaX1ocb2RhbmZmbG5sbm5MglIAwGI4cg</recordid><startdate>20230701</startdate><enddate>20230701</enddate><creator>Hamp, Austin</creator><creator>Hanson, Jamie</creator><creator>Alhatem, Albert</creator><creator>Schwartz, Robert A</creator><scope>7X8</scope></search><sort><creationdate>20230701</creationdate><title>Dupilumab-Associated Sezary Syndrome</title><author>Hamp, Austin ; Hanson, Jamie ; Alhatem, Albert ; Schwartz, Robert A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_miscellaneous_28766373773</frbrgroupid><rsrctype>reports</rsrctype><prefilter>reports</prefilter><language>eng</language><creationdate>2023</creationdate><toplevel>online_resources</toplevel><creatorcontrib>Hamp, Austin</creatorcontrib><creatorcontrib>Hanson, Jamie</creatorcontrib><creatorcontrib>Alhatem, Albert</creatorcontrib><creatorcontrib>Schwartz, Robert A</creatorcontrib><collection>MEDLINE - Academic</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hamp, Austin</au><au>Hanson, Jamie</au><au>Alhatem, Albert</au><au>Schwartz, Robert A</au><format>book</format><genre>unknown</genre><ristype>RPRT</ristype><atitle>Dupilumab-Associated Sezary Syndrome</atitle><jtitle>Indian journal of dermatology</jtitle><date>2023-07-01</date><risdate>2023</risdate><volume>68</volume><issue>4</issue><spage>459</spage><epage>462</epage><pages>459-462</pages><eissn>1998-3611</eissn><abstract>Dupilumab is a monoclonal antibody that inhibits interleukin-4 (IL-4) and interleukin-13 (IL-13), approved for the treatment of adults with moderate-to-severe atopic dermatitis (AD). While recent reports have described cases of new-onset mycosis fungoides (MF) following treatment with dupilumab for AD, to our knowledge only one patient has been delineated with the progression to SS. We present an additional case of a patient who was diagnosed with SS following treatment with dupilumab for adult-onset AD and asthma. We examine SS as a possible side effect of dupilumab while also discussing management and theories to explain this phenomenon.</abstract><doi>10.4103/ijd.ijd_580_22</doi></addata></record>
fulltext fulltext
identifier EISSN: 1998-3611
ispartof Indian journal of dermatology, 2023, Vol.68 (4), p.459-462
issn 1998-3611
language eng
recordid cdi_proquest_miscellaneous_2876637377
source PubMed Central Free; DOAJ Directory of Open Access Journals; PubMed Central Open Access; EZB-FREE-00999 freely available EZB journals
title Dupilumab-Associated Sezary Syndrome
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-20T07%3A09%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:book&rft.genre=unknown&rft.atitle=Dupilumab-Associated%20Sezary%20Syndrome&rft.jtitle=Indian%20journal%20of%20dermatology&rft.au=Hamp,%20Austin&rft.date=2023-07-01&rft.volume=68&rft.issue=4&rft.spage=459&rft.epage=462&rft.pages=459-462&rft.eissn=1998-3611&rft_id=info:doi/10.4103/ijd.ijd_580_22&rft_dat=%3Cproquest%3E2876637377%3C/proquest%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2876637377&rft_id=info:pmid/&rfr_iscdi=true